Vivendy Therapeutics AG's Treatment for Morbus Morquio (MPS IVA) Granted Orphan Drug Designation by FDA

Published: Sep 17, 2008

BASEL, Switzerland--(BUSINESS WIRE)--Vivendy Therapeutics Ltd. today announced that its enzyme replacement therapy (ERT) for Mucopolysaccharidosis IVA, (MPS IVA-Morbus Morquio) has been granted Orphan Drug designation by the United States Food and Drug Administration (FDA). This designation, following potential marketing approval in the future will give Vivendy seven years of market exclusivity and could facilitate the recovery of certain regulatory filing fees.

Back to news